Osumi, H., Shinozaki, E., Suenaga, M., Kumekawa, Y., Ogura, M., Ozaka, M., . . . Mizunuma, N. (2015). Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy? BMC Cancer.
Citação norma ChicagoOsumi, Hiroki, et al. "Does Anti-p53 Antibody Status Predict for Clinical Outcomes in Metastatic Colorectal Cancer Patients Treated With Fluoropyrimidine, Oxaliplatin, Plus Bevacizumab As First-line Chemotherapy?" BMC Cancer 2015.
ציטוט MLAOsumi, Hiroki, et al. "Does Anti-p53 Antibody Status Predict for Clinical Outcomes in Metastatic Colorectal Cancer Patients Treated With Fluoropyrimidine, Oxaliplatin, Plus Bevacizumab As First-line Chemotherapy?" BMC Cancer 2015.